ALOPECIA AREATA (AA)
Clinical trials for ALOPECIA AREATA (AA) explained in plain language.
Never miss a new study
Get alerted when new ALOPECIA AREATA (AA) trials appear
Sign up with your email to follow new studies for ALOPECIA AREATA (AA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New scalp injection trial aims to regrow hair in alopecia areata
Disease control Recruiting nowThis is an early-stage study to see if a new injectable solution called ALD-102 is safe and can help regrow hair in people with alopecia areata. Researchers will give small injections into the scalp every four weeks for two months and compare the results to untreated or placebo-t…
Matched conditions: ALOPECIA AREATA (AA)
Phase: PHASE1, PHASE2 • Sponsor: Aldena Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Doctors seek best first treatment for Kids' hair loss
Disease control Recruiting nowThis study aims to find out which of two common medications works better for children with moderate-to-severe alopecia areata, a condition causing patchy or total hair loss. Children and teens (ages 2-17) starting their first systemic treatment will choose, with their parents, to…
Matched conditions: ALOPECIA AREATA (AA)
Phase: PHASE4 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial seeks to calm overactive immune system
Disease control Recruiting nowThis is a first-in-human study to check if a new injectable drug called VIS171 is safe for people with certain autoimmune diseases like lupus, alopecia areata, or a kidney disease called FSGS. About 30 participants will receive the drug along with their standard care for up to a …
Matched conditions: ALOPECIA AREATA (AA)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New shot tested to regrow hair in autoimmune baldness
Disease control Recruiting nowThis is a first-in-human study to check the safety of an experimental drug called HCW9302 in people with alopecia areata, an autoimmune condition that causes hair loss. About 30 adults will receive injections, starting with low doses to monitor for side effects. The main goal is …
Matched conditions: ALOPECIA AREATA (AA)
Phase: PHASE1 • Sponsor: HCW Biologics • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC